BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.060
-0.030 (-2.75%)
At close: Apr 28, 2026, 4:00 PM EDT
1.070
+0.010 (0.94%)
Pre-market: Apr 29, 2026, 8:55 AM EDT

BioXcel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
29351986602569
Upgrade
Market Cap Growth
218.88%88.57%-78.51%-85.65%5.82%-49.47%
Upgrade
Enterprise Value
1101088396462317
Upgrade
Last Close Price
1.061.605.9847.20343.68325.28
Upgrade
PS Ratio
44.7054.508.1962.581605.17-
Upgrade
PB Ratio
--0.37-0.20-1.537.842.57
Upgrade
P/TBV Ratio
----7.842.57
Upgrade
EV/Sales Ratio
171.25168.3836.6969.821233.33-
Upgrade
Debt / Equity Ratio
-1.15-1.15-1.10-1.791.220.01
Upgrade
Net Debt / Equity Ratio
-0.85-0.85-0.78-0.63-1.30-1.05
Upgrade
Net Debt / EBITDA Ratio
-1.63-1.63-1.13-0.210.632.17
Upgrade
Net Debt / FCF Ratio
-1.41-1.41-1.01-0.230.742.81
Upgrade
Asset Turnover
0.020.020.040.010.00-
Upgrade
Inventory Turnover
0.230.231.610.63--
Upgrade
Quick Ratio
0.530.531.352.405.9013.98
Upgrade
Current Ratio
0.830.831.682.656.1714.21
Upgrade
Return on Equity (ROE)
----1766.94%-111.08%-49.93%
Upgrade
Return on Assets (ROA)
-75.47%-75.47%-72.30%-74.95%-44.81%-29.10%
Upgrade
Return on Capital Employed (ROCE)
557.90%557.90%-402.40%-361.00%-92.30%-48.00%
Upgrade
Earnings Yield
-243.55%-199.76%-321.18%-207.35%-27.54%-18.80%
Upgrade
FCF Yield
-200.76%-164.66%-388.15%-179.52%-22.51%-14.52%
Upgrade
Buyback Yield / Dilution
-381.58%-381.58%-39.21%-4.00%-6.23%-21.63%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.